Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Tuesday, June 30

I P O S T E R S E S O T ac

22400 Variable suppression of HIV-1 replication in patients treated with
nelfinavir in combination with AZT and 3TC for greater than two years
Martin Markowitz*; M.S. Vesanen; Y. Cao; D. Boden; M. Duran; M.R.
Chaudhry; N. Clendennin, USA
22401 Stavudine (d4T),didanosine (ddl) and ritonavir as a triple therapy in
antiretroviral-naive patients. Results at 72 weeks
Adrien G. Saimot*; Roland Landman; F. Damond; D. Mathez;
C. Gaudebout;. Leibowitch; A.G. Saimot; The IMEA 01 Study Group,
France
22402 Salvage therapy for antiretroviral failure in HIV+ patients
Alexandre Cavorus*; C.E. Thompson; P.D. Salvato, USA
22403 AZT + 3TC + indinavir vs D4T + 3TC + indinavir for HIV-infection in
pretreated patients with less than 200 CD4/MM3
Rafael Rubio*; J. Martin; F. Pulido; A. Barrios; J. Alcami; J.R. Costa, Spain
22404 Pharmacokinetic interaction between nevirapine and indinavir and
correlation with antiviral activity
Robert Murphy*; J.P. Sommadossi; M. Lamson; P. Gagnier; D. Hall;
M. Myers;A. Dusek, USA
22405 Increase in the expenditure for antiretroviral drugs: Are there any
advantages?
Matteo Bassetti*; A. Di Biagio; B. Rebesco; M.E. Amalfitano; G. Gatti;
F. Fusco; D. Bassetti, Italy
22406 Scenario of anti retroviral therapy (ART) in 25,000 HIV/AIDS individuals
in Mumbai-lndia
DattaraySaple*;J.K. Maniar, India
22407 Cell fusion infectivity assay in patients receiving retroviral therapy
Maria Angelica Watanabe*;J.C. Voltarelli; P. V.B. Palma; M.D. Orellana;
V.B. Valente; S. Kashima; D.T. Covas, Brazil
22408 Antiretroviral combination therapy in patients with low CD4 cell counts
Dundu Malaki Dwili*; S. T. Datel, Kenya
22409 Efficacy and safety profile of antiretroviral treatment of ritonavir in
combination with zidovudine (ZDV/AZT) and zalcitabine (ddC) for HIV/
AIDS patients in San Lazaro Hospital
Dominic Garcia*; E.G. Santiago; M.A. Manalo; C.C. dela Cruz;
E.D. de las Alas; J.M. Maala, Philippines
22410 Experience with saquinavir zalcitabine zidovudine triple combination
Denes Binhegyi*;J. Szldvik; Z. Gerlei; d. Gyuris; J. MinRaacute;rovics,
Hungary
22411 Immune reconstitution of HIV discordant monozygotic twins: Insight
into T cell dynamics
Chris Tsoukas*; H. Turner;]. Goodhew; D. Kilby; C. Kovaks;J.
Luetkehoelter; S. Walmsley;J.P. Routy; N. Bernard, Canada
22412 Changes in lymphocyte subsets with interleukin-2 therapy in patients
with advanced HIV disease on highly active antiretroviral therapy
(HAART)
Daniel Berger*; B.E. Baker; G. Bucher; R. Bessinger; P. Maroni; W.M. Reiter,
USA
22413 Experience with proleukin (rlL2) in HIV-infected patients
Anne-Marie Duliege*; W. Capra; M. Giedlin;M. Owens, USA

22414 A randomised clinical trial of d4T + 3TC + SQV + NFV with or without
interleukin-2 in early HIV-infection: Preliminary results
Haws-Juergen Stellbrink*; J. van Lunzen; A. Adam; C. Hoffmann;
B. Kuhlmann; S. Fenske; G. Schmidt-Hartnack; S.P. Aries; 0. Degen; C.
Schneider; F.T. Hufert; K. Tenner-Racz; P. Racz, Germany
22415 Phenotypic expressions of CCR5-62/832 homozygosity
Thomas R. O'Brien*; G.T. Nguyen;J.J. Goedert;M. Carrington; M. Dean;
SJ. O'Brien, USA
22416 Chemokines and chemokine receptors expression during combined anti
HIV-1 IL-2 therapy
Julia Blanco; C. Cabrera; L. Ruiz;A. Jou; B. Clotet;J.A. Este, Spain
22417 Immunological parameters modified in HIV disease by the macrophage
activity immunomodulator WF10 (A phase II pathogenesis study)
Brian Herndier*; R. Lull; 0. Ah Ching; M. Broz; F. W. Kuehne; J. Kahn, USA
22418 Immunotherapy for HIV-1 infection using DNA-based vaccines
David Weiner*;Jean Boyer; K.E. Ugen; M. Bennett; A. Cohen;
M.L. Bagarazzi; A. Jaradian; R. Ciccarelli, USA
22419 Increased CD4+ T cell response to IL-2 therapy in HIV-1-infected
individuals heterozygous for CCR5632
Graeme Stewart*; R. Biti; P. Williamson;A. Clegg; D. Cooper; S. Emery;
A. Carr, Australia
22420 Randomized, controlled phase II trial ofS.C. interleukin-2 in
HIV-patients
Ulrich Hengge*; V. Exner; S. Esser; C. Borchard; K. Mueller; M. T.H. Eppner;
M. Goos, Germany
22421 Successful immune reconstitution over four years after thymic
transplantation in an AIDS patient
Andre Nahmias*; R. Hong; C. Ibegbu; F. Lee; A. Kourtis; P. Parker; E. Klein,
USA
22422 Phase 1/11 trial of HIVIG for the prevention of HIV-1 vertical transmission
in Uganda
J.B. Jackson*; F. Mmiro; L. Guay; P. Musoke; C. Fletcher; P. Kataaha;
L. Falksveden, USA
22423 A single center, phase 2 study evaluating the effects ofWF10
James 0. Kahn*; Michael S. Mc Grath; OM. Ah Ching; FW. Kuhne, USA
22424 Inhibition of HIV-1 replication in reservoir cells by the safe
immunomodulator Murabutide
Georges Bahr*; E. Darcissac; 0. Grau; M.J. Truong;J. Dewulf; C. Debard;
A. Capron, France
22425 No title indicated by the author
Dennis Leon*; M.A. Rodriguez; VM. Rodriguez; C.A. Soto; M. Calderon,
Costa Rica
22426 Euthanasia:The opinion of Europeans with HIV-infection
Yon Fleerackers*; R. Andraghetti; J.C.C. Borleffs; N. Ferro; P. Sas;
R. Colebunders; Eurosupport Group, Belgium
22427 Palliative care for HIV-infection in a skilled nursing facility
Peter A. Selwyn*; K.P. Fennie; S. Molde; J. Constantino, Sr.; P. Wetherill;
L. Goldman; C. Kennedy, USA
22428 Pain in HIV disease: A Moroccan survey
Abdelfattah Chakib*; S.E. Nejmi; 0. Hliwa; H. Himmich, Morocco

94

'th World AIDS Conference Geneva